Influenza Medication Market was valued US$ XX Bn in 2018 and is expected to reach US$ 477.84 Bn by 2027, at CAGR of XX% during forecast period of 2019 to 2027.
Influenza Medication Market
Influenza Medication Market Drivers and Restrains:
Influenza medication contain antiviral drugs that are used in reaction to disease influenza. Influenza (flu), is a viral infection that attacks respiratory system like nose, throat and lungs. It is a viral infectious disease that includes three major types like A, B, and type C. The common symptoms of the disorder are cold, cough, fever, and sore throat, which can be severe or mild. The major classes of antiviral drugs used against influenza are neuraminidase inhibitors, such as zanamivir and oseltamivir, or inhibitors of the viral M2 protein, such as amantadine and rimantadine. These drugs can decrease the severity of symptoms and to reduce the risk of infection.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.
The unmet medical needs within the annual influenza epidemics along with strong R&D focus resulting in new and advanced treatments and drugs, and increasing demand due to government stockpiling that are major driving factor of the market growth. For example, According to the CDC, nearby X% to XX% of the population is affected with the flu in the U.S. every year. Moreover, an expected XX people are hospitalized due to flu infection in the U.S. every year; of these XX% die due to flu complications. Favorable policies for treatment and prevention of influenza by the government in developed regions. These are the major drivers in the growth of influenza medication market. Patent expiry of key drugs and entry of generics and side effects of anti-influenza drug therapy are hamper the market growth globally.
Influenza Medication Market Segmentation Analysis:
Based on the distribution channels, the influenza medication market has been segmented into pharmacies, hospitals and clinics. The pharmacies segment held the largest share accounting around XX% share of global market in 2018 owing to increase in the number of pharmacy stores Patients discharged from hospitals or clinics with an influenza treatment plan to use influenza medication for a prescribed treatment duration prefer online or retail pharmacy purchase. The hospitals segment is hold the substantial market share of XX% in 2018. Hospitals normally preferred distribution channel segment, as the patients with HIV and cardiovascular disease related with Influenza. In hospitals, increasing incidence of influenza in-patients drives the growth of this segment.
Based on the product, the influenza medication market has been segmented into zanamivir, oseltamivir, peramivir, amantadine, rimantadine, and inosine. The oseltamivir segment held a significant share of XX% in the global market in 2018 owing to the rising use of oseltamivir in the treatment of flu triggered by H1N1 virus and prophylaxis.
Influenza Medication Market Regional Analysis:
Geographically, the influenza medication market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the Influenza medication market in 2018. The U.S. lead the Influenza medication market in North America owing to increasing acceptance of advanced and high-cost drug therapies, increased treatment rate, and favorable reimbursement policies in the country. The market in Asia Pacific is expected to expand at a high CAGR of XX% during the forecast period due to major contribution from developing countries, availability of low cost treatment and availability of better health care facilities. Increase in the number of public awareness programs for prevention and diagnosis of chronic diseases such as influenza has significantly reduced the incidence of influenza in Asia Pacific. China and India are highly populated countries with the maximum number of influenza patients making them major contributor to the growth of the market in Asia Pacific.
Influenza Medication Market Competitive landscape
Major Key players operating in this market are Daiichi Sankyo Company, GlaxoSmithKline plc, Natco Pharma, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd. Manufacturers in the Influenza Medication are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.
The objective of the report is to present comprehensive analysis of influenza medication market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding influenza medication market dynamics, structure by analyzing the market segments, and project the influenza medication market size. Clear representation of competitive analysis of key players by product type, price, financial position, product portfolio, growth strategies, and regional presence in the influenza medication market make the report investor’s guide.
Scope of the Influenza Medication Market:
Influenza Medication Market, by Product type:
Influenza Medication Market, by Distribution Channel:
Influenza Medication Market, by Region:
- Asia Pacific
- North America
- Latin America
- Middle East Africa
Influenza Medication Market, Major Players:
- Daiichi Sankyo Company
- GlaxoSmithKline plc
- Natco Pharma
- F. Hoffmann-La Roche Ltd.
- Teva Pharmaceutical Industries Ltd.
- Sandoz International GmbH
- Sun Pharmaceutical Industries Ltd.
- Mylan, Inc.
- Emirates SkyCargo
Report Is Submitted By : Maximize Market Research Company
Customization of the report:
Maximize Market Research of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.
About Maximize Market Research:
Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.